OncoMed's rosmantuzumab lacks clinical benefit in Phase I for solid tumors

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said IV rosmantuzumab (OMP-131R10) every two weeks "failed to provide compelling evidence of clinical benefit" in an open-label, U.S. Phase Ia/Ib trial to t...